FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3099362012> ?p ?o ?g. }

• W3099362012 endingPage "130" @default.
• W3099362012 startingPage "129" @default.
• W3099362012 abstract "Background: Chronic fatigue is a well-known symptom in patients with rheumatic diseases and other immune-mediated inflammatory diseases (IMIDs). Therefore, fatigue as an adverse drug reaction (ADR) to biologics may remain unrecognised or may erroneously be attributed to the disease. Objectives: To assess patient-reported fatigue attributed to biologics for IMIDs and investigate predisposing factors of patient-reported fatigue. Methods: The Dutch Biologic Monitor is a multicenter patient-reported ADR monitoring system that surveys patients using a biologic for an IMID. Patients completed web-based questionnaires regarding ADRs attributed to biologics and the course and experienced burden (5 point Likert scale) of these ADRs. All patient-reported ADRs with MedDRA Preferred Term ‘fatigue’ were defined as biologic-associated fatigue (BA-fatigue). Basic demographics and treatment characteristics were compared between patients reporting BA-fatigue and patients not reporting BA-fatigue (reported other ADRs or no ADRs). Results: Out of 1369 participating IMID patients, 696 patients reported 1844 unique ADRs. BA-fatigue was reported by 100 patients and 48 patients described a consistent pattern of recurring fatigue after each administration. Most of these patients (88%) described recovery from BA-fatigue within one week after biologic administration and 73 patients reported health care professional (HCP) contact following BA-fatigue, with dose adjustment in 8 and discontinuation in 5 patients. Basic demographics and characteristics that differ significantly between patients reporting BA-fatigue and patients not reporting BA-fatigue are summarized in table 1. No significant difference was found for other biologics, IMIDs, combination therapy and comorbidities. BA-fatigue was reported by 27% of rituximab users (n=33), 27% of vedolizumab users (n=26), 16% of tocilizumab users (n=50), 14% of infliximab users (n=159) and 3% of etanercept users (n=418). Although 29 patients in the BA-fatigue population had RA and 29 patients had Crohn’s disease (CD), 571 patients in our overall study population had RA and 194 patients had CD, suggesting BA-fatigue was reported by CD patients more often. The mean burden of BA-fatigue was higher than the mean burden of other ADRs (p<0.001). Table 1. Characteristics of patients with BA-fatigue compared to patients with other ADRs and without ADRs Patients with BA-fatigue n (%) Patients with other ADRs n (%) Patients without ADRs n (%) n 100 (100%) 596 (100%) 673 (100%) Basic demographics Age (years) (mean ± SD) 50.0 ± 14.6 53.4 ± 13.6 * 55.7 ± 14.2 *** Gender (Female) 59 (59%) 398 (67%) ns 342 (51%) ns Smoking n (%) 25 (25%) 97 (16%) * 100 (15%) * BMI (kg/m 2 ) (mean ± SD) 25.7 ± 4.4 25.9 ± 4.7 ns 26.6 ± 5.5 ns Biologic Infliximab 22 (22%) 53 (9%) *** 84 (12%) * Etanercept 13 (13%) 177 (30%) *** 228 (34%) *** Rituximab 9 (9%) 18 (3%) ** 6 (1%) *** Tocilizumab 8 (8%) 29 (5%) ns 13 (2%) ** Vedolizumab 7 (7%) 12 (2%) * 7 (1%) *** IMID Rheumatoid arthritis 29 (29%) 270 (45%) ** 272 (40%) * Crohn’s disease 29 (29%) 77 (13%) *** 88 (13%) *** Other indication 16 (16%) 53 (9%) * 39 (6%) *** Combination therapy Methotrexate 23 (23%) 167 (28%) ns 227 (34%) * Comorbidity Psychiatric disorder 11 (11%) 49 (8%) ns 31 (5%) * Other comorbidity 30 (30%) 124 (21%) * 102 (15%) *** Mean burden of ADR ± SD 2.9 ± 0.9 2.4 ± 1.1 *** Mann Whitney U, independent t-test and Fisher’s exact as appropriate ns: not significant *p ≤ 0.05 **p ≤ 0.01 ***p ≤ 0.001 Conclusion: HCPs should be aware that fatigue may be associated with biologic therapy and has a significant burden on patients. Evaluating the course of the symptoms might be helpful in recognizing BA-fatigue. Disclosure of Interests: Jette van Lint: None declared, Tom Bakker: None declared, Jouke Ubbink: None declared, Martijn van Doorn Grant/research support from: Unrestricted grants, advisory board, speaker fees and/or other (investigator) from Novartis, Abbvie, Janssen Cilag, Leopharma and Pfizer, Speakers bureau: Unrestricted grants, advisory board, speaker fees and/or other (investigator) from Novartis, Abbvie, Janssen Cilag, Leopharma and Pfizer, Phyllis Spuls Grant/research support from: Departmental independent research grant for TREAT NL registry LeoPharma December 2019; Contract support: I am involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of e.g. psoriasis and atopic dermatitis for which we get financial compensation paid to the department/hospital, Consultant of: Consultancies in the past for Sanofi 111017 and AbbVie 041217 (unpaid), Sander Tas: None declared, Harald Vonkeman: None declared, Frank Hoentjen Grant/research support from: Received grants from Dr Falk, Janssen-Cilag, and AbbVie., Consultant of: Served on advisory boards, or as speaker or consultant for AbbVie, Celgene, Janssen-Cilag, MSD, Takeda, Celltrion, Teva, Sandoz, and Dr Falk, Speakers bureau: Served on advisory boards, or as speaker or consultant for AbbVie, Celgene, Janssen-Cilag, MSD, Takeda, Celltrion, Teva, Sandoz, and Dr Falk, Bart van den Bemt Grant/research support from: UCB, Pfizer and Abbvie, Consultant of: Delivered consultancy work for UCB, Novartis and Pfizer, Speakers bureau: Pfizer, AbbVie, UCB, Biogen and Sandoz., Michael Nurmohamed Grant/research support from: Not related to this research, Consultant of: Not related to this research, Speakers bureau: Not related to this research, Eugène van Puijenbroek: None declared, Naomi Jessurun: None declared" @default.
• W3099362012 created "2020-11-23" @default.
• W3099362012 creator A5006478983 @default.
• W3099362012 creator A5027180965 @default.
• W3099362012 creator A5033556021 @default.
• W3099362012 creator A5037224353 @default.
• W3099362012 creator A5065003334 @default.
• W3099362012 creator A5067384016 @default.
• W3099362012 creator A5072786878 @default.
• W3099362012 creator A5073876435 @default.
• W3099362012 creator A5076851753 @default.
• W3099362012 creator A5082092098 @default.
• W3099362012 creator A5083604090 @default.
• W3099362012 creator A5091151755 @default.
• W3099362012 date "2020-06-01" @default.
• W3099362012 modified "2023-10-17" @default.
• W3099362012 title "OP0208 PATIENTS REPORT FATIGUE AS AN ADVERSE DRUG REACTION OF BIOLOGICS" @default.
• W3099362012 doi "https://doi.org/10.1136/annrheumdis-2020-eular.1310" @default.
• W3099362012 hasPublicationYear "2020" @default.
• W3099362012 type Work @default.
• W3099362012 sameAs 3099362012 @default.
• W3099362012 citedByCount "1" @default.
• W3099362012 countsByYear W30993620122023 @default.
• W3099362012 crossrefType "journal-article" @default.
• W3099362012 hasAuthorship W3099362012A5006478983 @default.
• W3099362012 hasAuthorship W3099362012A5027180965 @default.
• W3099362012 hasAuthorship W3099362012A5033556021 @default.
• W3099362012 hasAuthorship W3099362012A5037224353 @default.
• W3099362012 hasAuthorship W3099362012A5065003334 @default.
• W3099362012 hasAuthorship W3099362012A5067384016 @default.
• W3099362012 hasAuthorship W3099362012A5072786878 @default.
• W3099362012 hasAuthorship W3099362012A5073876435 @default.
• W3099362012 hasAuthorship W3099362012A5076851753 @default.
• W3099362012 hasAuthorship W3099362012A5082092098 @default.
• W3099362012 hasAuthorship W3099362012A5083604090 @default.
• W3099362012 hasAuthorship W3099362012A5091151755 @default.
• W3099362012 hasBestOaLocation W30993620121 @default.
• W3099362012 hasConcept C126322002 @default.
• W3099362012 hasConcept C1862650 @default.
• W3099362012 hasConcept C197934379 @default.
• W3099362012 hasConcept C2778715236 @default.
• W3099362012 hasConcept C2910384678 @default.
• W3099362012 hasConcept C512399662 @default.
• W3099362012 hasConcept C71924100 @default.
• W3099362012 hasConceptScore W3099362012C126322002 @default.
• W3099362012 hasConceptScore W3099362012C1862650 @default.
• W3099362012 hasConceptScore W3099362012C197934379 @default.
• W3099362012 hasConceptScore W3099362012C2778715236 @default.
• W3099362012 hasConceptScore W3099362012C2910384678 @default.
• W3099362012 hasConceptScore W3099362012C512399662 @default.
• W3099362012 hasConceptScore W3099362012C71924100 @default.
• W3099362012 hasIssue "Suppl 1" @default.
• W3099362012 hasLocation W30993620121 @default.
• W3099362012 hasOpenAccess W3099362012 @default.
• W3099362012 hasPrimaryLocation W30993620121 @default.
• W3099362012 hasRelatedWork W1965393569 @default.
• W3099362012 hasRelatedWork W1999318505 @default.
• W3099362012 hasRelatedWork W2063006222 @default.
• W3099362012 hasRelatedWork W2399404195 @default.
• W3099362012 hasRelatedWork W2466043692 @default.
• W3099362012 hasRelatedWork W2595635579 @default.
• W3099362012 hasRelatedWork W2766844642 @default.
• W3099362012 hasRelatedWork W3007321116 @default.
• W3099362012 hasRelatedWork W3114253099 @default.
• W3099362012 hasRelatedWork W4362546065 @default.
• W3099362012 hasVolume "79" @default.
• W3099362012 isParatext "false" @default.
• W3099362012 isRetracted "false" @default.
• W3099362012 magId "3099362012" @default.
• W3099362012 workType "article" @default.